上海醫藥股票討論區

The company's consistent ROCE and capital increase hint at a lack of high return investments. High current liabilities to total assets ratio may pose risks. The stock's low return to shareholders over the past five years shows lackluster trends.

Shanghai Pharmaceuticals Holding's declining earnings and anticipated lower growth may signal a less prosperous future. This, combined with a lack of earnings growth improvement, could prevent a significant share price increase in the near term.

The market may have anticipated the fall in EPS, or it might expect the situation to get better. Dividend payments largely explain the divergence between the TSR and share price return over five years. Significant improvement in fundamental performance is needed to reverse the downward trend in the stock value.

The company's poor and stagnant return on capital invested, the surge in capital used, and the significant short-term debt obligations suggest a lackluster performance. It doesn't exhibit the traits of a prospective multi-bagger stock.